Currently, there are 88.80M common shares owned by the public and among those 65.76M shares have been available to trade.
The company’s stock has a 5-day price change of 78.23% and 97.23% over the past three months. VERV shares are trading 101.77% year to date (YTD), with the 12-month market performance up to 103.21% higher. It has a 12-month low price of $2.86 and touched a high of $9.31 over the same period. VERV has an average intraday trading volume of 3.47 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 105.02%, 129.05%, and 98.33% respectively.
Institutional ownership of Verve Therapeutics Inc (NASDAQ: VERV) shares accounts for 74.01% of the company’s 88.80M shares outstanding.
It has a market capitalization of $1.01B and a beta (3y monthly) value of 1.72. The earnings-per-share (ttm) stands at -$2.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 30.17% over the week and 13.74% over the month.
Earnings per share for the fiscal year are expected to decrease by -3.29%, and -13.19% over the next financial year. EPS should grow at an annualized rate of -0.31% over the next five years, compared to -42.43% over the past 5-year period.
H.C. Wainwright coverage for the Verve Therapeutics Inc (VERV) stock in a research note released on April 08, 2024 offered a Buy rating with a price target of $15. Canaccord Genuity was of a view on April 13, 2023 that the stock is Buy, while Cantor Fitzgerald gave the stock Neutral rating on February 01, 2023, issuing a price target of $21. Goldman on their part issued Sell rating on December 15, 2022.
